Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?

Célia Cintas; Julie Guillermet-Guibert

doi:10.3389/fonc.2017.00330

Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?

Front Oncol. 2018 Jan 22:7:330. doi: 10.3389/fonc.2017.00330. eCollection 2017.

Authors

Célia Cintas^{1

2}, Julie Guillermet-Guibert^{1

2}

Affiliations

¹ INSERM U1037, CRCT, Université Toulouse III Paul Sabatier, Toulouse, France.
² Laboratoire d'Excellence TouCAN, Toulouse, France.

No abstract available

Keywords: data integration; genomics; isoform specificity; phosphatidylinositol-3-kinase pathway; precision medicine; predictor of therapeutic response; proteomics; transcriptomics.